Selected article for: "NTP nucleotide triphosphate and nucleotide triphosphate"

Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response
  • Document date: 2020_4_14
  • ID: d7stppv5_11
    Snippet: We developed a pharmacokinetic / pharmacodynamic model of remdesivir (Fig. 3a) , a broad-spectrum nucleotide analogue that targets SARS CoV-2 replication in infected cells (16) . The model links intravenous administration with plasma levels of free drug and concentrations of the drug's active nucleotide-triphosphate component (NTP) observed within PBMCs in nonhuman primates (17) , and captures the slow decay of NTP within this compartment (Fig. 3.....
    Document: We developed a pharmacokinetic / pharmacodynamic model of remdesivir (Fig. 3a) , a broad-spectrum nucleotide analogue that targets SARS CoV-2 replication in infected cells (16) . The model links intravenous administration with plasma levels of free drug and concentrations of the drug's active nucleotide-triphosphate component (NTP) observed within PBMCs in nonhuman primates (17) , and captures the slow decay of NTP within this compartment (Fig. 3b) .

    Search related documents:
    Co phrase search for related documents
    • broad spectrum and infected cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • broad spectrum and intravenous administration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • broad spectrum and nucleotide analogue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • broad spectrum and nucleotide triphosphate: 1, 2
    • concentration free drug and free drug: 1, 2, 3
    • concentration free drug and plasma level: 1
    • free drug and plasma level: 1
    • infected cell and intravenous administration: 1, 2
    • infected cell and nonhuman primate: 1, 2
    • infected cell and plasma level: 1
    • infected cell and slow decay: 1
    • intravenous administration and nonhuman primate: 1
    • intravenous administration and nucleotide analogue: 1
    • intravenous administration and nucleotide triphosphate: 1, 2
    • intravenous administration and pharmacokinetic pharmacodynamic model: 1
    • intravenous administration and plasma level: 1, 2
    • NTP slow decay and slow decay: 1